Bristol University spin-out Ziylo has been acquired by Danish pharmaceutical Novo Nordisk for over $800 million. Novo Nordisk now has full rights to Ziylo’s glucose binding molecule platform to develop glucose responsive insulins. The deal is one of the largest for a Univesity of Bristol spin-out.
Bristol Diabetes Spin-Out Acquired By Novo Nordisk For $800M
